Trubion Announces Completion Of Enrollment And Dosing Of Patients In Phase IIb Clinical Trial Of TRU-015 For The Treatment Of Rheumatoid Arthritis
Thu, 18 Jan 2007 08:00 AM EST
... Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced it has completed enrollment and dosing of patients in its Phase IIb clinical trial of TRU-015, the Company's lead Small Modular ImmunoPharmaceutical (SMIP(TM)) drug candidate for the treatment of rheumatoid arthritis (RA). [click link for full article] ...
Related Topics
- Clinical Trials
- Rheumatoid Arthritis
- Arthritis
- Juvenile Rheumatoid Arthritis
- Rheumatoid Factor
- Rituximab
- Arthritis, Rheumatoid
- Septic Arthritis
- Infliximab
- Adalimumab
- Reactive Arthritis
- Osteoarthritis
- Treatment
- Pharmacology
- Pancreatic Cancer
- Trastuzumab
- Treatments
- Psychopharmacology
- Crohn's Disease
- Tarceva

Not Signed In -


